DADC
CLSD

D.A. Davidson & Co’s Clearside Biomedical CLSD Stock Holding History

D.A. Davidson & Co’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-833
Closed -$19K – 1023
2020
Q3 		$19K Buy
833
+133
+19% +$3.44K ﹤0.01% 947
2020
Q2 		$20K Buy
+700
New +$20.6K ﹤0.01% 926

Other funds holding CLSD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

D.A. Davidson & Co's CLSD Position: Q4 2020 in Review

D.A. Davidson & Co sold out of Clearside Biomedical (CLSD) in Q4 2020, closing a stake of 833 shares — an estimated $19K sold.

D.A. Davidson & Co first reported a position in CLSD in Q2 2020 and held it in 2 quarters. The position peaked at $20K in Q2 2020. 42 funds tracked by Wall St. Rank hold CLSD as of Q4 2020.

  • D.A. Davidson & Co reported no remaining Clearside Biomedical position as of Q4 2020 after selling out during the quarter.
  • D.A. Davidson & Co sold 833 Clearside Biomedical shares in Q4 2020, an estimated $19K.
  • D.A. Davidson & Co first reported a position in Clearside Biomedical in Q2 2020 and held it in 2 quarters.
  • D.A. Davidson & Co's Clearside Biomedical position peaked at $20K in Q2 2020.
  • 42 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2020.

Based on D.A. Davidson & Co's 13F filing for Q4 2020, filed 10 Feb 2021.